[go: up one dir, main page]

WO1997032891B1 - Conjugate for modifying interactions between proteins - Google Patents

Conjugate for modifying interactions between proteins

Info

Publication number
WO1997032891B1
WO1997032891B1 PCT/DE1997/000458 DE9700458W WO9732891B1 WO 1997032891 B1 WO1997032891 B1 WO 1997032891B1 DE 9700458 W DE9700458 W DE 9700458W WO 9732891 B1 WO9732891 B1 WO 9732891B1
Authority
WO
WIPO (PCT)
Prior art keywords
conjugate
receptor
polypeptides
conjugate according
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/DE1997/000458
Other languages
German (de)
French (fr)
Other versions
WO1997032891A3 (en
WO1997032891A2 (en
Filing date
Publication date
Priority claimed from DE19608813A external-priority patent/DE19608813C2/en
Priority to DE59708952T priority Critical patent/DE59708952D1/en
Priority to US09/142,471 priority patent/US7112436B1/en
Priority to EP97919258A priority patent/EP0888384B1/en
Priority to AT97919258T priority patent/ATE229542T1/en
Priority to DK97919258T priority patent/DK0888384T3/en
Application filed filed Critical
Priority to JP53135697A priority patent/JP4301575B2/en
Publication of WO1997032891A2 publication Critical patent/WO1997032891A2/en
Publication of WO1997032891A3 publication Critical patent/WO1997032891A3/en
Publication of WO1997032891B1 publication Critical patent/WO1997032891B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Abstract

The present invention concerns a conjugate comprising two polypeptides with a mutual affinity and connected via a linker. It also concerns the use of such a conjugate to modify interactions between proteins.

Claims

GEÄNDERTE ANSPRÜCHE[beim Internationalen Büro am 12. Januar 1998 (12.01.98) eingegangen; ursprüngliche Ansprüche 1-15 durch geänderte Ansprüche 1-12 ersetzt (2 Seiten)! AMENDED CLAIMS [received at the International Bureau on 12 January 1998 (12.01.98); original claims 1-15 replaced by amended claims 1-12 (2 pages)! 1 . Konjugat, umfassend zwei, eine Affinität zueinander aufweisende, Polypeptide, wobei die Polypeptide über einen Linker miteinander verbunden sind, dadurch gekennzeichnet, daß der Linker eine durch die zwei Polypeptide ausgebildete Disulfidbrücke oder ein Polypeptid ist.1 . A conjugate comprising two affinities with one another, wherein the polypeptides are linked together by a linker, characterized in that the linker is a disulfide bridge formed by the two polypeptides or a polypeptide. 2. Konjugat nach Anspruch 1 , dadurch gekennzeichnet, daß das eine Polypeptid ein Rezeptor und das andere ein den Rezeptor bindender Ligand ist.2. A conjugate according to claim 1, characterized in that the one polypeptide is a receptor and the other is a receptor binding ligand. 3. Konjugat nach Anspruch 2, dadurch gekennzeichnet, daß der Rezeptor in Form seiner den Liganden bindenden Untereinheit vorliegt.3. A conjugate according to claim 2, characterized in that the receptor is present in the form of its ligand binding subunit. 4. Konjugat nach Anspruch 2 oder 3, dadurch gekennzeichnet, daß der Ligand in Form semer den Rezeptor bindenden Untereinheit vorliegt.4. A conjugate according to claim 2 or 3, characterized in that the ligand is present in the form of semer receptor binding subunit. 5. Konjugat nach einem der Ansprüche 2-4, dadurch gekennzeichnet, daß der Rezeptor ein Zytokin-Rezeptor und der Ligand ein Zytokin ist.5. A conjugate according to any one of claims 2-4, characterized in that the receptor is a cytokine receptor and the ligand is a cytokine. 6. Konjugat nach Anspruch 5, dadurch gekennzeichnet, daß der Zytokm- Rezeptor ein IL-6 Rezeptor und das Zytokin ein IL-6 ist.6. A conjugate according to claim 5, characterized in that the cytokine receptor is an IL-6 receptor and the cytokine is an IL-6. 7. Konjugat nach Anspruch 5, dadurch gekennzeichnet, daß der Zytokin- Rezeptor ein CNTF-Rezeptor und das Zytokin ein CNTF ist.7. A conjugate according to claim 5, characterized in that the cytokine receptor is a CNTF receptor and the cytokine is a CNTF. 8. Konjugat nach einem der Ansprüche 1 - 7, dadurch gekennzeichnet, daß das Konjugat ein Fusionspolypeptid ist. - 14 -8. A conjugate according to any one of claims 1-7, characterized in that the conjugate is a fusion polypeptide. - 14 - 9. DNA, kodierend für das Konjugat nach Anspruch 8.9. DNA encoding the conjugate according to claim 8. 10. Expressionsplasmid, umfassend die DNA nach Anspruch 9.10. An expression plasmid comprising the DNA according to claim 9. 1 1 . Transformante, enthaltend das Expressionsplasmid nach Anspruch 10.1 1. A transformant containing the expression plasmid according to claim 10. 1 2. Verwendung des Konjugats nach einem der Ansprüche 1 - 8 und der DNA nach Anspruch 9 zur Beeinflussung der Wechselwirkungen zwischen Proteinen. 1 2. Use of the conjugate according to any one of claims 1-8 and the DNA according to claim 9 for influencing the interactions between proteins. - 15 -- 15 - IN ARTIKEL 19 GENANNTE ERKLÄRUNGDECLARATION REFERRED TO IN ARTICLE 19 I) Als Stand der Technik werden die folgenden Druckschriften genannt:I) The following publications are mentioned as prior art: (D1 ) Stoyan et al., European Journal of Biochemistry, Bd.(D1) Stoyan et al., European Journal of Biochemistry, Vol. 21 6, Nr. 1 , S. 239-245 ( 1 993) (D2) Ehlers et al., Journal of Immunology, Bd. 1 53, Nr. 4, S.21 6, No. 1, pp. 239-245 (1 993) (D2) Ehlers et al., Journal of Immunology, Vol. 1 53, No. 4, p. 1 744-1 753 ( 1 994) (D3) WO-A-96/043141 744-1 753 (1 994) (D3) WO-A-96/04314 (D4) US-A-5 260 203(D4) US-A-5,260,203 (D5) WO-95/1 5341(D5) WO-95/1 5341 (D6) Sui et al. , Proceed. of the National Academy of(D6) Sui et al. , Proceed. of the National Academy of Sciences USA, Bd. 92, S. 2859-2863 ( 1 995) (D7) Fischer et al., Nature Biotechnology, Bd. 1 5, Nr. 2, S.Sciences USA, Vol. 92, pp. 2859-2863 (1,995) (D7) Fischer et al., Nature Biotechnology, Vol. 1 5, No. 2, p. 142-145 (Febr. 1 997)142-145 (Feb. 1 997) II) Der geänderte Anspruch 1 betrifft nun ein Konjugat, umfassend zwei, eine Affinität zueinander aufweisende Polypeptide, wobei die Polypeptide über einen Linker miteinander verbunden sind, dadurch gekennzeichnet, daß der Linker eine durch die zwei Polypeptide ausgebildete Disulfidbrücke oder ein Polypeptid ist.II) The amended claim 1 now relates to a conjugate comprising two polypeptides having affinity for one another, wherein the polypeptides are linked together by a linker, characterized in that the linker is a disulfide bridge formed by the two polypeptides or a polypeptide. III) Gegenüber dem im Recherchenbericht genannten Stand der Technik ist der Gegenstand der vorliegenden Anmeldung neu und erfinderisch. In keiner der zahlreichen Entgegenhaltungen D1 -D6 ist ein Konjugat gezeigt oder nahegelegt, das zwei eine Affinität zueinander aufweisende Polypeptide umfaßt, wobei die Polypeptide über einen Linker miteinander verbunden sind und das dadurch gekennzeichnet ist, daß der Linker eine durch die zwei Polypeptide ausgebildete Disulfidbrücke oder ein Polypeptid ist. D7 stellt als P,X-Doku- ment keinen Stand der Technik dar, da von wirksamer Inanspruchnahme der Priorität ausgegangen wird. III) Compared with the prior art mentioned in the search report, the subject of the present application is novel and inventive. None of the numerous references D1-D6 disclose or suggest a conjugate comprising two affinity polypeptides, wherein the polypeptides are linked by a linker and characterized in that the linker forms a disulfide bridge formed by the two polypeptides is a polypeptide. D7 does not represent a state of the art as a P, X document, as it is assumed that the priority is being used effectively.
PCT/DE1997/000458 1996-03-07 1997-03-07 Conjugate for modifying interactions between proteins Ceased WO1997032891A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP53135697A JP4301575B2 (en) 1996-03-07 1997-03-07 Conjugates to influence interactions between proteins
US09/142,471 US7112436B1 (en) 1996-03-07 1997-03-07 Conjugate for modifying interactions between proteins
EP97919258A EP0888384B1 (en) 1996-03-07 1997-03-07 Fusion polypeptide for modifying interactions between proteins
AT97919258T ATE229542T1 (en) 1996-03-07 1997-03-07 FUSION POLYPEPTIDE FOR INFLUENCING INTERACTIONS BETWEEN PROTEINS
DK97919258T DK0888384T3 (en) 1996-03-07 1997-03-07 Fusion polypeptide to influence interactions between proteins
DE59708952T DE59708952D1 (en) 1996-03-07 1997-03-07 FUSION POLYPEPTIDE FOR INFLUENCING INTERACTIONS BETWEEN PROTEINS

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19608813A DE19608813C2 (en) 1996-03-07 1996-03-07 Conjugate for influencing interactions between proteins
DE19608813.5 1996-03-07

Publications (3)

Publication Number Publication Date
WO1997032891A2 WO1997032891A2 (en) 1997-09-12
WO1997032891A3 WO1997032891A3 (en) 1998-02-05
WO1997032891B1 true WO1997032891B1 (en) 1998-03-19

Family

ID=7787490

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE1997/000458 Ceased WO1997032891A2 (en) 1996-03-07 1997-03-07 Conjugate for modifying interactions between proteins

Country Status (9)

Country Link
US (1) US7112436B1 (en)
EP (1) EP0888384B1 (en)
JP (1) JP4301575B2 (en)
AT (1) ATE229542T1 (en)
DE (2) DE19608813C2 (en)
DK (1) DK0888384T3 (en)
ES (1) ES2188935T3 (en)
PT (1) PT888384E (en)
WO (1) WO1997032891A2 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217858B1 (en) 1997-02-11 2001-04-17 Hadasit & Medical Research Services & Development Company, Ltd. Pharmaceutical composition for treating hepatitis B virus (HBV) infection
IL122818A0 (en) * 1997-07-10 1998-08-16 Yeda Res & Dev Chimeric interleukin-6 soluble receptor/ligand protein analogs thereof and uses thereof
EP2316944A3 (en) * 2000-06-16 2011-11-02 Asterion Limited Binding agents: chimeric ligand/receptor proteins
DE10107737A1 (en) * 2001-02-16 2002-09-05 S Rose John Christian Albrecht Use of a conjugate of IL-6 and an IL-6 receptor for tumor therapy
WO2003092579A2 (en) * 2002-04-29 2003-11-13 Hadasit Medical Research Services And Development Company Ltd. Compositions and methods for treating cancer with an oncolytic viral agent
EP1400587A1 (en) * 2002-09-19 2004-03-24 MainGen Biotechnologie GmbH Use of a fusion polypeptide for obtaining pluripotent non-embryonic stem cells
IL161672A0 (en) 2004-04-29 2004-09-27 Yeda Res & Dev Compositions and methods for therapy of chemotherapy-induced neuropathy
EP1598364A1 (en) * 2004-05-21 2005-11-23 AGIRx Limited Chimerical soluble hyper IL-11 receptor and use thereof
DE102004033122A1 (en) * 2004-07-08 2006-02-09 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Apparatus and method for analyzing interactions between biomolecules
PL1899364T5 (en) 2005-05-17 2024-12-09 University Of Connecticut Compositions and methods for immunomodulation in an organism
JP5266460B2 (en) * 2005-06-16 2013-08-21 ハダジット メディカル リサーチ サービシズ アンド ディベラップメント リミテッド Methods for treating renal failure
EP1777294A1 (en) * 2005-10-20 2007-04-25 Institut National De La Sante Et De La Recherche Medicale (Inserm) IL-15Ralpha sushi domain as a selective and potent enhancer of IL-15 action through IL-15Rbeta/gamma, and hyperagonist (IL15Ralpha sushi -IL15) fusion proteins
EP2366787B1 (en) 2006-01-13 2019-12-11 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Codon optimized IL-15 and IL-15R-Alpha genes for expression in mammalian cells
WO2008100292A2 (en) 2006-10-16 2008-08-21 Genelux Corporation Modified vaccinia virus strains for use in diagnostic and therapeutic methods
ES2716476T3 (en) 2007-06-27 2019-06-12 Us Health IL15 and IL15Ralfa complexes and their uses
US20110182848A1 (en) * 2007-08-03 2011-07-28 Asterion Limited Granulocyte colony stimulating factor
GB0715213D0 (en) * 2007-08-06 2007-09-12 Asterlon Ltd Igf-1
EP2217264B8 (en) * 2007-11-28 2013-02-27 Hadasit Medical Research Services and Development Ltd. Use of an il-6/il-6 receptor complex for preventing xerostomia induced by radiotherapy or chemotherapy
EP2300023A2 (en) * 2008-05-16 2011-03-30 Genelux Corporation Microorganisms for preventing and treating neoplasms accompanying cellular therapy
EP2387415A1 (en) * 2009-01-16 2011-11-23 AGIRx Limited Vaccine compositions
JP2013501817A (en) 2009-08-14 2013-01-17 アメリカ合衆国 Use of IL-15 for treatment of increased thymic output and lymphopenia
WO2011151716A1 (en) 2010-06-04 2011-12-08 Lupin Limited Process for the purification of recombinant human il-11
JP6280031B2 (en) 2012-03-29 2018-02-14 中外製薬株式会社 Anti-LAMP5 antibody and use thereof
CN105324124A (en) 2013-04-19 2016-02-10 赛腾制药 Cytokine-derived therapy for reduced vascular leak syndrome
EP2915569A1 (en) 2014-03-03 2015-09-09 Cytune Pharma IL-15/IL-15Ralpha based conjugates purification method
EP2992898A1 (en) 2014-09-04 2016-03-09 Klinikum rechts der Isar der Technischen Universität München T-cell adjuvant and its use for therapeutic or prophylactic vaccination
CN110055224B (en) * 2019-04-03 2023-06-30 深圳市体内生物医药科技有限公司 Genetically modified immune cell and preparation method and application thereof
EP3875111A1 (en) 2020-03-05 2021-09-08 Poznan University Of Medical Sciences Stem cell cancer vaccine composition

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
GB9324807D0 (en) * 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
EP0776339B2 (en) * 1994-07-29 2010-01-20 Sunol Molecular Corporation Mhc complexes and uses thereof

Similar Documents

Publication Publication Date Title
WO1997032891B1 (en) Conjugate for modifying interactions between proteins
DE69233528T2 (en) Process for the preparation of multivalent antigen-binding proteins
DE3785186T2 (en) BINDING MOLECULE WITH SINGLE POLYPEPTIDE CHAIN.
Knapp Archaeology, annales, and ethnohistory
EP0835934A3 (en) Muteins of streptavidin
EP1985706A3 (en) Di- or oligomer of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins
CA2155185A1 (en) Totally synthetic affinity reagents
AU1873199A (en) Method of identifying binding site domains that retain the capacity of binding to an epitope
CA2164984A1 (en) Recombinant disulfide-stabilized polypeptide fragments having binding specificity
DE68916537D1 (en) PRODUCTION OF AN INSULIN-LIKE GROWTH FACTOR-BINDING PROTEIN.
CA2081028A1 (en) Cd2 binding domain of lymphocyte function associated antigen 3
ATE61407T1 (en) MUTEINS OF BIOLOGICALLY ACTIVE PROTEINS WITH REDUCED CYSTEIN CONTENT, THEIR PRODUCTION, FORMULATIONS CONTAINING SUCH MUTEINS AND STRUCTURAL GENES, VECTORS AND ORGANISMS SUITABLE FOR THE PRODUCTION OF SAID MUTEINS AND THEIR PRODUCTION.
RU94045919A (en) Antibodies, cells, polypeptide, dna, vectors, method of polypeptide preparing, method of antibody preparing, pharmaceutical composition
CA2095852A1 (en) Proteins with changed epitopes and methods for the production thereof
DE3855421D1 (en) Modular assembly of antibody genes, antibodies produced thereby and their application
CA2380331A1 (en) Multiple cytokine-antibody complexes
DE69535948D1 (en) WDP-40 ABREGING PEPTIDES AND THEIR USE
AU4162400A (en) Derivatives of the b or z domain from staphylococcal protein a (spa) interactingwith at least one domain of human factor viii
KR950005324A (en) Insulin preparations
ATE140029T1 (en) PRODUCTION OF BIOLOGICALLY ACTIVE INSULIN-LIKE GROWTH FACTOR I FROM HIGH EXPRESSION HOST CELL SYSTEMS
CA2195076A1 (en) Process for modifying the stability of antibodies
KR960701899A (en) Protein Complexes Having Factor VIII: C Activity and Their Preparation
KR910020033A (en) Mutant of granulocyte stimulator (G-CSF)
CA2075974A1 (en) Totally synthetic affinity reagents
CA2019671A1 (en) Oxidative denaturation of protein analytes